54062 recent Wall Street rating changes — with our own star rating shown next to every analyst we independently track.
Track the latest analyst rating changes from Wall Street brokerages: stock upgrades, downgrades and price-target revisions, updated through the day. Unlike a plain ratings feed, every change here is matched — where we can — to the analyst's independent track record on 13Foresight, so you can see at a glance whether the person behind the call has actually been accurate. Analysts we rank show a ★★★★☆ score and link to their full performance page; firms link to their pooled track record. Use the tabs below to filter by change type.
| When | Stock | Change | Analyst | Rating | Price Target |
|---|---|---|---|---|---|
|
Aug 12
12:08 UTC
|
SEPN
Septerna
|
◎ Target | Raghuram Selvaraju not yet tracked | Buy | $40.00→ $60.00+50.0% |
|
Aug 12
12:08 UTC
|
QUIK
QuickLogic
|
◎ Target | Neil Young not yet tracked | Buy | $22.00→ $20.00-9.1% |
|
Aug 12
12:08 UTC
|
ONON
ON
|
◎ Target | Cristina Fernandez ★★★☆☆ #1387 | Outperform | $51.00→ $43.00-15.7% |
|
Aug 12
12:08 UTC
|
ONON
ON
|
◎ Target | Jonathan Komp ★★☆☆☆ #2320 | Outperform | $70.00→ $55.00-21.4% |
|
Aug 12
12:08 UTC
|
OMDA
Omada Health
|
◎ Target | Vikram Kesavabhotla ★★☆☆☆ #2693 | Neutral | $15.00→ $25.00+66.7% |
|
Aug 12
12:08 UTC
|
NGNE
Neurogene
|
◎ Target | Mitchell S. Kapoor not yet tracked | Buy | $70.00→ $65.00-7.1% |
|
Aug 12
12:08 UTC
|
LITE
Lumentum
|
◎ Target | Vivek Arya ★★☆☆☆ #2766 | Neutral | $1,100.00→ $1,000.00-9.1% |
|
Aug 12
12:08 UTC
|
IPHA
Innate Pharma
|
◎ Target | Jeet Mukherjee ★★★☆☆ #2210 | Buy | $8.00→ $9.00+12.5% |
|
Aug 12
12:08 UTC
|
HBT
HBT Financial
|
◎ Target | firm only | Outperform | $40.00→ $44.00+10.0% |
|
Aug 12
12:08 UTC
|
EXOD
Exodus Movement
|
◎ Target | Gareth Gacetta not yet tracked | Overweight | $14.00→ $15.00+7.1% |
|
Aug 12
12:08 UTC
|
ETOR
eToro Group
|
◎ Target | Nathan Frankovitz not yet tracked | Overweight | $61.00→ $53.00-13.1% |
|
Aug 12
12:08 UTC
|
ETOR
eToro Group
|
◎ Target | John Todaro ★☆☆☆☆ #3195 | Buy | $66.00→ $53.00-19.7% |
|
Aug 12
12:08 UTC
|
ERAS
Erasca
|
◎ Target | Andres Y. Maldonado ★★☆☆☆ #2639 | Buy | $18.00→ $22.00+22.2% |
|
Aug 12
12:08 UTC
|
ELE
Elemental Royalty
|
◎ Target | Heiko F. Ihle not yet tracked | Buy | $32.50→ $33.00+1.5% |
|
Aug 12
12:08 UTC
|
CRWV
CoreWeave
|
◎ Target | Brett Knoblauch ★☆☆☆☆ #3209 | Overweight | $167.00→ $176.00+5.4% |
|
Aug 12
12:08 UTC
|
CRWV
CoreWeave
|
◎ Target | Rob Oliver not yet tracked | Outperform | $100.00→ $130.00+30.0% |
|
Aug 12
12:08 UTC
|
CLMT
Calumet
|
◎ Target | firm only | Hold | $34.00→ $40.00+17.6% |
|
Aug 12
12:08 UTC
|
CAVA
CAVA Group
|
◎ Target | Andrew M. not yet tracked | Buy | $100.00→ $85.00-15.0% |
|
Aug 12
12:08 UTC
|
CAH
Cardinal Health
|
◎ Target | Eric Coldwell ★★★★☆ #755 | Outperform | $251.00→ $274.00+9.2% |
|
Aug 12
12:08 UTC
|
BLTE
Belite Bio
|
◎ Target | Yi Chen ★★☆☆☆ #2462 | Buy | $200.00→ $214.00+7.0% |
|
Aug 12
12:08 UTC
|
BCAX
Bicara Therapeutics
|
◎ Target | Jeet Mukherjee ★★★☆☆ #2210 | Buy | $28.00→ $39.00+39.3% |
|
Aug 12
12:08 UTC
|
ARMK
Aramark
|
◎ Target | Andrew Wittmann ★★★★☆ #418 | Outperform | $63.00→ $69.00+9.5% |
|
Aug 12
12:08 UTC
|
APP
AppLovin
|
◎ Target | Clark Lampen ★★☆☆☆ #2728 | Buy | $574.00→ $408.00-28.9% |
|
Aug 12
12:08 UTC
|
AMTM
Amentum
|
◎ Target | Andre Madrid ★★☆☆☆ #2823 | Buy | $35.00→ $30.00-14.3% |
|
Aug 12
12:08 UTC
|
AMBQ
Ambiq Micro
|
◎ Target | N. Quinn Bolton not yet tracked | Buy | $70.00→ $85.00+21.4% |
|
Aug 12
12:08 UTC
|
AFRM
Affirm
|
◎ Target | Rufus Hone not yet tracked | Outperform | $78.00→ $86.00+10.3% |
|
Aug 12
12:08 UTC
|
ACAD
ACADIA Pharmaceuticals
|
◎ Target | Ami Fadia ★★★☆☆ #2060 | Buy | $38.00→ $41.00+7.9% |
|
Aug 12
12:07 UTC
|
ONON
ON
|
↓ Downgrade | Strong Buy not yet tracked | Strong-Buy→ Outperform | $52.00→ $38.00-26.9% |
|
Aug 12
12:07 UTC
|
LEGN
Legend Biotech
|
↓ Downgrade | firm only | Outperform→ Market Perform | |
|
Aug 12
12:07 UTC
|
GAP
GAP
|
↓ Downgrade | Corey Tarlowe ★★★★☆ #565 | Buy→ Hold | $23.00 |
|
Aug 12
12:07 UTC
|
APGE
Apogee Therapeutics
|
↓ Downgrade | Julian Harrison ★★☆☆☆ #2856 | Buy→ Neutral | |
|
Aug 12
12:07 UTC
|
SMWB
Similarweb
|
↑ Upgrade | firm only | Market Perform→ Outperform | $10.00 |
|
Aug 12
12:07 UTC
|
ISRG
Intuitive Surgical
|
↑ Upgrade | Suraj Kalia ★★★★★ #324 | Market Perform→ Outperform | $500.00 |
|
Aug 12
12:07 UTC
|
ENTG
Entegris
|
↑ Upgrade | Melissa Weathers ★★☆☆☆ #2563 | Hold→ Buy | $152.00→ $200.00+31.6% |
|
Aug 12
11:18 UTC
|
ULVR
Unilever
|
◎ Target | firm only | Underperform | GBX 3,800→ GBX 3,900+2.6% |
|
Aug 12
11:18 UTC
|
TW
Taylor Wimpey
|
◎ Target | firm only | Buy | GBX 102→ GBX 101-1.0% |
|
Aug 12
11:18 UTC
|
SHC
Shaftesbury Capital
|
◎ Target | firm only | Buy | GBX 185→ GBX 195+5.4% |
|
Aug 12
11:18 UTC
|
PSN
Persimmon
|
◎ Target | firm only | Buy | GBX 1,591→ GBX 1,590-0.1% |
|
Aug 12
11:18 UTC
|
GEN
Genuit Group
|
◎ Target | firm only | Buy | GBX 332→ GBX 366+10.2% |
|
Aug 12
11:18 UTC
|
DRX
Drax Group
|
◎ Target | firm only | Buy | GBX 920→ GBX 870-5.4% |
|
Aug 12
11:18 UTC
|
BWY
Bellway
|
◎ Target | firm only | Buy | GBX 2,394→ GBX 2,380-0.6% |
|
Aug 12
11:18 UTC
|
BNZL
Bunzl
|
↓ Downgrade | firm only | Hold | GBX 2,950→ GBX 3,000+1.7% |
|
Aug 12
11:03 UTC
|
ONON
ON
|
↓ Downgrade | Strong Buy not yet tracked | Strong-Buy→ Outperform | $38.00 |
|
Aug 12
11:03 UTC
|
GAP
GAP
|
↓ Downgrade | Corey Tarlowe ★★★★☆ #565 | Buy→ Hold | |
|
Aug 12
10:15 UTC
|
ONON
ON
|
↓ Downgrade | Strong Buy not yet tracked | Strong-Buy→ Outperform | |
|
Aug 12
10:15 UTC
|
MRCY
Mercury Systems
|
↓ Downgrade | firm only | Hold | |
|
Aug 12
10:15 UTC
|
DSRLF
DiaSorin
|
↓ Downgrade | firm only | Neutral→ Sell | |
|
Aug 12
10:15 UTC
|
BZLFY
Bunzl
|
↓ Downgrade | firm only | Buy→ Hold | |
|
Aug 12
10:15 UTC
|
ENTG
Entegris
|
↑ Upgrade | James Schneider ★★☆☆☆ #2465 | Sell→ Buy | |
|
Aug 12
10:15 UTC
|
ENTG
Entegris
|
↑ Upgrade | Melissa Weathers ★★☆☆☆ #2563 | Hold→ Buy | $200.00 |
An analyst rating change is when a Wall Street brokerage updates its recommendation on a stock — an upgrade (e.g. Hold → Buy), a downgrade (e.g. Buy → Sell), or a price-target revision (raising or lowering the expected share price). This page lists the most recent changes across U.S. markets.
Where we independently track the analyst, each change shows our own star rating and accuracy rank, computed from real historical price performance — not the brokerage's own marketing. That lets you judge whether the analyst behind a call has actually been right before.
The feed refreshes several times a day, so new upgrades, downgrades and price-target changes appear the same day they are published. Each row shows the date and time we recorded it.
No. A rating change is one analyst's opinion, not investment advice. Track records vary widely — which is exactly why we attach each analyst's independent accuracy. Always do your own research.